Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2020 - 2026)

Monte Rosa Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$8000.0 for Q1 2026.

• In Q1 2026, Other Non Operating Income fell 104.62% year-over-year to -$8000.0; the TTM figure through Mar 2026 stood at $1.3 million (up 4303.23% YoY), while the FY2025 annual figure was $1.5 million, up 256.73% from the prior year.
• Other Non Operating Income was -$8000.0 for Q1 2026 at Monte Rosa Therapeutics, up from -$50000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $1.4 million in Q2 2025 to a low of -$779000.0 in Q4 2023.
• Historically, Other Non Operating Income has averaged $57176.5 across 5 years, with a median of -$8000.0 in 2026.
• Biggest YoY gain for Other Non Operating Income was 2722.64% in 2025; the steepest drop was 2600.0% in 2025.
• A 5-year view of Other Non Operating Income shows it stood at -$283000.0 in 2022, then sank by 175.27% to -$779000.0 in 2023, then soared by 100.26% to $2000.0 in 2024, then plunged by 2600.0% to -$50000.0 in 2025, then jumped by 84.0% to -$8000.0 in 2026.
• The last three Other Non Operating Income figures came in at -$8000.0 (Q1 2026), -$50000.0 (Q4 2025), and -$29000.0 (Q3 2025), per Business Quant data.